Aldeyra Therapeutics, Inc. (ALDX)
$
5.39
+0.09 (1.67%)
Key metrics
Financial statements
Free cash flow per share
-350.1 Thousand
Market cap
322.8 Million
Price to sales ratio
1.3 Thousand
Debt to equity
0.2814
Current ratio
2.8633
Income quality
1.0674
Average inventory
0
ROE
-0.7066
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aldeyra Therapeutics, Inc. is a biotechnology company that specializes in developing and commercializing innovative treatments for immune-mediated ocular and systemic diseases. The company reported an income before tax of -$55,851,000.00 showcasing its pre-tax profitability, and it achieved a revenue of $0.00 indicating its niche market focus. Furthermore, the income before tax ratio is 0.00 reflecting the pre-tax margin. As part of its financial operations, the company incurred an interest expense of $1,926,000.00 which underscores its debt servicing obligations. Additionally, the net total of other income and expenses is $4,266,000.00 reflecting non-core financial activities. Aldeyra's lead product candidate, reproxalap, currently in Phase III clinical trials, aims to address dry eye diseases and allergic conjunctivitis. The company is also advancing ADX-629, a first-in-class orally administered RASP modulator presently in Phase II trials for psoriasis, asthma, and COVID-19, alongside ADX-2191, a dihydrofolate reductase inhibitor that is in Phase 3 for the prevention of proliferative vitreoretinopathy and Phase II for retinitis pigmentosa and primary vitreoretinal lymphoma. Additionally, Aldeyra has a license agreement with Madrigal Pharmaceuticals, Inc. for the development of ADX-1612, which targets the protein chaperome for treating inflammatory diseases. The company, originally founded as Aldexa Therapeutics, Inc., rebranded to Aldeyra Therapeutics, Inc. in March 2014 and is headquartered in Lexington, Massachusetts. In the current market landscape, Aldeyra’s stock is affordable at $5.01 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 1,031,825.00 indicating lower market activity. With a market capitalization of $322,837,284.00 the company is classified as a small-cap player in the biotechnology field. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth within the healthcare domain. As Aldeyra Therapeutics continues to develop its product pipeline, it remains committed to addressing urgent medical needs while achieving financial growth and stability.
Is Aldeyra Therapeutics, Inc. (ALDX) a good investment?
Investing in Aldeyra Therapeutics, Inc. (ALDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Aldeyra Therapeutics, Inc. (ALDX)'s stock forecast?
Analysts predict Aldeyra Therapeutics, Inc. stock to fluctuate between $1.14 (low) and $7.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aldeyra Therapeutics, Inc.'s market capitalization?
As of 2025-08-18, Aldeyra Therapeutics, Inc.'s market cap is $322,837,284, based on 59,895,600 outstanding shares.
How does Aldeyra Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Aldeyra Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aldeyra Therapeutics, Inc. (ALDX) stock?
To buy Aldeyra Therapeutics, Inc. (ALDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALDX. Place an order (Market, Limit, etc.).
What is the best time to invest in Aldeyra Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Aldeyra Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.94 | Growth: 46.88%.
Where can I find Aldeyra Therapeutics, Inc.'s investor relations reports?
Visit https://www.aldeyra.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aldeyra Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aldeyra Therapeutics, Inc. stock?
All-time high: $11.97 (2023-06-15) | All-time low: $1.14 (2025-04-03).
What are the key trends affecting Aldeyra Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
seekingalpha.com
Aldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for December 2025. After that, AbbVie may pay $100 million upfront and share US profits if Reproxalap wins approval, which should materially de-risk its eventual commercialization.
globenewswire.com
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
prnewswire.com
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
globenewswire.com
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
See all news
